Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab versus adalimumab in children with enthesitis-related arthritis and juvenile psoriatic arthritis
NL-OMON55112Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in juvenile idiopathic arthritis, enthesitis-related (JIA-ERA), juvenile psoriatic arthritis (JPsA) and juvenile ankylosing spondylitis (JAS) comparing Ixekizumab with Adalimumab reference arm (2 arms). Started Sep 2021; status: recruiting.
02
Drugs
ixekizumabadalimumab
03
Conditions
juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)juvenile psoriatic arthritis (JPsA)juvenile ankylosing spondylitis (JAS)
Beyond the preview
Go deeper on NL-OMON55112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55112.